Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902235 | 0.88 | SLC6A2 (0.40) | SLC6A2SLC6A4KCNA3SLC6A3KCNA2 | |
| SCHEMBL13912658 | 0.79 | SLC6A2 (0.37) | SLC6A2SLC6A4KCNA3 | |
| SCHEMBL348555 | 0.78 | ALDH1A1 (0.40) | — | |
| SCHEMBL4094258 | 0.76 | MAPT (0.38) | SLC6A2SLC6A4KCNA3 | |
| SCHEMBL4097077 | 0.76 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2794298 | 0.71 | AKR1C1 (0.47) | SLC6A2SLC6A4HCAR3HCAR2 | |
| SCHEMBL8110728 | 0.69 | AKR1C1 (0.58) | SLC6A2SLC6A4KCNA3HCAR3HCAR2 | |
| SCHEMBL8112526 | 0.69 | AKR1C1 (0.53) | SLC6A2SLC6A4KCNA3HCAR3HCAR2 | |
| SCHEMBL2874416 | 0.67 | AKR1C1 (0.56) | KCNA3HCAR3HCAR2 | |
| SCHEMBL5637245 | 0.67 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400660-A | Triazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | SLC6A2 1397/4885SLC6A4 704/4885KCNA3 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.